Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven in Docetaxel-Pretreated HRPC
NCT00124566Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of irofulven in prostate cancer (PCa) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Time to Progression (RECIST) and Time to Progression (PSA). Started Jun 2004; status: completed.
02
Drugs
irofulven
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00124566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124566.